Insider Buying: Cipher Pharmaceuticals (TSE:CPH) Director Acquires C$283,200.00 in Stock

Cipher Pharmaceuticals Inc. (TSE:CPH) (NASDAQ:CPHR) Director Craig Mull acquired 20,000 shares of the stock in a transaction that occurred on Friday, September 18th. The shares were bought at an average price of C$14.16 per share, with a total value of C$283,200.00. Following the completion of the purchase, the director owned 1,009,953 shares in the company, valued at C$14,300,934.48. The trade was a 2.02% increase in their ownership of the stock.

Cipher Pharmaceuticals Stock Performance

Shares of CPH stock opened at C$14.06 on Friday. Cipher Pharmaceuticals Inc. has a fifty-two week low of C$12.48 and a fifty-two week high of C$20.56. The stock’s 50-day moving average is C$15.19 and its two-hundred day moving average is C$16.50. The company has a debt-to-equity ratio of 0.27, a current ratio of 1.59 and a quick ratio of 2.67. The firm has a market cap of C$357.00 million, a P/E ratio of 12.55 and a beta of 1.05.

Cipher Pharmaceuticals (TSE:CPH) (NASDAQ:CPHR) last announced its earnings results on Tuesday, August 11th. The company reported C$0.21 earnings per share for the quarter. The company had revenue of C$17.14 million during the quarter. Cipher Pharmaceuticals had a net margin of 58.81% and a return on equity of 22.74%. Analysts predict that Cipher Pharmaceuticals Inc. will post 1.2907348 earnings per share for the current fiscal year.

About Cipher Pharmaceuticals

Cipher Pharmaceuticals (TSX: CPH) (OTCQX: CPHRF) is a specialty pharmaceutical company with a robust and diversified portfolio of commercial and early to late-stage products, mainly in dermatology. Cipher acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and currently markets those products in Canada, the U.S., and South America.